|
|
|
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA
|
As we all know well, “unearthing” our molecules’ potential poses numerous technical and business-related challenges for young biotech companies. Here, Werner and I continue our conversation, unpacking some of these internal and external challenges the company is navigating as it strives to bring tRNA to the commercial market.
|
|
|
|
|
|
|
How many mRNAs are too many in a multivalent therapy? In this clip, Eliquent Life Science’s Tiffany Lucas and CureVac’s Ulrike Jägle delve into this question, emphasizing the factors that are essential for regulatory success and patient benefit.
|
|
|
|
|
|
By Jeanette Ampudia, biopharma analytical expert
|
Lessons learned from developing potency assays to detect activity and variation for cell- and receptor-mediated products — beyond the comforts of a well-heeled company.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
How mRNA Manufacturers Disrupt The Industry
|
|
Webinar | Sartorius
|
Learn how biopharmaceutical companies can apply proven strategies to overcome hidden complexities in mRNA production, and discover solutions that can help you rapidly design and build a SU facility.
|
|
|
|
|
|
|
|
|
|
Introduction To mRNA Manufacturing
|
|
Article | Cytiva
|
The SARS-CoV-2 virus has changed the course of scientific research around mRNA. Learn about mRNA manufacturing, the structure of an mRNA molecule, RNase-free considerations, and more.
|
|
|
|
|
|
|
.png){kind=logo}
